Risk scores are statistical indicators based on prescribing patterns compared to specialty peers. They are NOT allegations of fraud, misconduct, or improper care. Many legitimate medical reasons can explain outlier prescribing.
Read our methodology →Risk Flags
Risk indicators are statistical patterns, not allegations. Learn more
20,702
Total Claims
$8.6M
Drug Cost
1,148
Beneficiaries
$7,513
Cost/Patient
Risk Score Breakdown 3/100
Score components are additive. Read full methodology
Peer Comparison vs. 6,382 Endocrinology providers
+91%
Cost per patient vs peers
$7,513 vs $3,933 avg
+12%
Brand preference vs peers
57.1% vs 51.2% avg
Brand vs Generic
Brand: 10,838 claims · $7.6M
Generic: 8,135 claims · $967K
Top Prescribed Drugs
| Drug (Generic) | Claims | Cost |
|---|---|---|
| Dulaglutide | 1,572 | $1.7M |
| Semaglutide | 864 | $892K |
| Empagliflozin | 1,186 | $803K |
| Metformin Hcl | 174 | $756K |
| Insulin Aspart | 731 | $474K |
| Dapagliflozin Propanediol | 656 | $428K |
| Semaglutide | 330 | $346K |
| Sitagliptin Phosphate | 354 | $252K |
| Insulin Glargine,hum.Rec.Anlog | 509 | $208K |
| Insulin Glargine,hum.Rec.Anlog | 393 | $205K |
| Linagliptin | 315 | $197K |
| Sitagliptin Phos/Metformin Hcl | 253 | $156K |
| Insulin Degludec | 257 | $135K |
| Insulin Lispro | 189 | $130K |
| Tirzepatide | 88 | $113K |
Prescribing Profile
Patient Profile
74
Avg Age
64%
Female
1.86
Avg Risk Score
Explore More
Data from CMS Medicare Part D Prescriber Public Use File, 2023. Risk scores are statistical indicators, not allegations of wrongdoing.Methodology · About · Dispute this data